George Rieveschl, Inventor of Benadryl, Dies
CINCINNATIUniversity of Cincinnati (UC) alumnus and engineering professor emeritus George Rieveschl, PhD, known for inventing Benadryl, the worlds first effective antihistamine, died today at Christ Hospital, Cincinnati. He was 91.
A long-time supporter of the
Dr. Rieveschl was also the founding chairman of the University Foundation Board of Trustees.
Rieveschl was a chemistry professor at UC when he invented Benadryl.
He found to this surprise that a two-part compound he was originally testing to improve muscle-relaxing medications dramatically blocked histamine, the naturally released chemical that narrows air passages in the lungs and causes inflammation.
This breakthrough led, in 1946, to Benadryls becoming the first FDA-approved prescription antihistamine. First produced by Parke, Davis and Company, the drug is now distributed over-the-counter by the Parke-Davis division of Pfizer.
A 1937 alumnus of UC, Dr. Rieveschl spent 26 years working in the chemical industry as both a scientist and a consultant before returning to UC in 1970.
He is survived by his wife, Ellen, and two sons.
George Rieveschl, PhD
Jane Henney, MD, presents Benadryl inventor George Rieveschl, PhD, with a city proclamation noting May 16 as "60 Years of Benadryl" day.
Related Stories
UC experts say proper produce washing is key defense against Cyclospora
July 17, 2026
Hamilton County Public Health reports confirmed cases of cyclosporiasis, as concerns persist. Cyclospora is a parasite that can cause a stomach illness lasting days — sometimes even weeks. University of Cincinnati medical experts say it is usually linked to contaminated water or food, often fresh produce.
UC students organize free health clinic in community
July 15, 2026
The University of Cincinnati student chapter of Remote Area Medical held its annual free health clinic July 11-12 at St. Xavier High School. Medical, dental and vision care was offered to adults and children, with no income requirements or insurance needed.
University of Cincinnati advances FLASH radiation therapy with new clinical trial
July 15, 2026
UC Cancer Center researchers led the FAST-02 trial, showing ultra-high-dose-rate FLASH proton therapy near the heart and lungs safely reduced pain from thoracic bone metastases.